Manufacturing
Medical Devices
Medical

Boston Scientific

$37.62
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.29 (0.77%) Today
-$0.53 (-1.39%) After Hours

Why Robinhood?

You can buy or sell BSX and other stocks, options, ETFs, and crypto commission-free!

About

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg. Read More The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease, and other cardiovascular disorders including structural heart conditions. The Rhythm Management segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal, and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Employees
32,000
Headquarters
Marlborough, Massachusetts
Founded
1979
Market Cap
52.42B
Price-Earnings Ratio
32.07
Dividend Yield
0.00
Average Volume
7.42M
High Today
$38.26
Low Today
$37.62
Open Price
$37.73
Volume
2.96M
52 Week High
$41.00
52 Week Low
$26.27

Collections

Manufacturing
Medical Devices
Medical
Health
Technology
Business Services
US
North America

News

Yahoo FinanceMar 19

Boston Scientific (BSX) Rides on Acquisitions, Innovation

On Mar 18, we issued an updated research report on Boston Scientific Corporation BSX. The company’s recent acquisitions have added various products (though many are under development) with immense potential to its portfolio.

236
Yahoo FinanceMar 19

Boston Scientific's EP Arm Gets a Lift From Study Success

Boston Scientific Corporation BSX has moved a step ahead with its Electrophysiology business on the latest positive outcome related to the company’s LUMINIZE RF (Radiofrequency) Balloon Catheter.

54
Yahoo FinanceMar 18

BofA Lowers Boston Scientific Revenue Estimates On FDA Warning, But Keeps Buy Rating

A Food and Drug Administration warning about possible dangers from balloons and stents coated with the drug paclitaxel is bad news for Boston Scientific Corporation (NYSE: BSX)’s Eluvia stent, but Bank of America Merrill Lynch is still recommending the stock on the basis of the company’s broad overall portfolio.

286

Earnings

$0.31
$0.34
$0.38
$0.41
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 24, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.